BMS 986205

Drug Profile

BMS 986205

Alternative Names: BMS986205; ONO-7701

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Solid tumours

Most Recent Events

  • 23 Nov 2017 Bristol-Myers Squibb plans a phase I trial for Cancer (In volunteers) in November 2017 (NCT03346837)
  • 13 Nov 2017 Safety and efficacy data from a phase I/IIa trial in Cancer released by Bristol Myers Squibb
  • 09 Nov 2017 Phase-I clinical trials in Cancer (Monotherapy, In volunteers) in USA (PO) (NCT03362411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top